Tuesday’s Trading Day
| 25.08 | +0.15 / +0.60% |
Data as of May 21 | Day’s Change | |
| 23.50 | -1.58 / -6.30% |
| Volume: 900.00 |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $541.1M |
Company Description
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. It focused on the development and commercialization of Feraheme injection for intravenous or IV, use to treat iron deficiency anemia or IDA. The company engages in manufacture, development and commercialization of products derived from its proprietary technology for use in treating human diseases. AMAG Pharmaceuticals was founded in November 1981 and is headquartered in Lexington, MA.
Employees

Shareholders
| Other institutional | 57.48% |
| Mutual fund holders | 38.58% |
| Individual stakeholders | 27.37% |
Top Executives
| William K. Heiden, MBA | President, Chief Executive Officer & Director |
| Frank E. Thomas, CPA | Chief Operating Officer & Executive Vice President |
| Scott A. Holmes, MBA | Treasurer, CAO, VP-Finance & Controller |
| Scott T. McMillan, PhD | Senior VP-Quality & Technical Operations |
| Greg Madison | Chief Commercial Officer & Executive VP |